QIAGEN launches fourth-generation QuantiFERON®-TB Gold Plus in the U.S.

Germantown, Maryland, and Hilden, Germany, October 5, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available on October 9, 2017 for diagnostic use following U.S. Food and Drug Administration approval in June.

Read More →

France to reimburse IGRAs to screen at-risk individuals for latent TB

The French decision to reimburse interferon-gamma release assays (IGRAs) for TB screening includes QuantiFERON-TB® Gold Plus (QFT-Plus®) and T-SPOT®.TB Test.

Read More →

FDA approves fourth generation latent TB blood test

NEW YORK, June 8, 2017 – Qiagen said today that its QuantiFeron-TB Gold Plus (QFT-Plus) blood test for detecting latent tuberculosis infection has received US Food and Drug Administration approval.

Read More →

Qiagen: Response to TAG, TB CAB, India CAB open letter

Qiagen's response to the open letter sent by TAG, TB CAB and India CAB re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries.

Read More →

Page 1 of 1 · Total posts: 4